174 related articles for article (PubMed ID: 17465210)
1. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
Law KS; Chen HC; Liao SK
Anticancer Res; 2007; 27(2):841-50. PubMed ID: 17465210
[TBL] [Abstract][Full Text] [Related]
2. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
4. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro.
Michalakis J; Georgatos SD; de Bree E; Polioudaki H; Romanos J; Georgoulias V; Tsiftsis DD; Theodoropoulos PA
Ann Surg Oncol; 2007 Mar; 14(3):1220-8. PubMed ID: 17206477
[TBL] [Abstract][Full Text] [Related]
5. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
6. Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis.
Peng B; Chang Q; Wang L; Hu Q; Wang Y; Tang J; Liu X
Gynecol Oncol; 2008 Jan; 108(1):173-81. PubMed ID: 17959232
[TBL] [Abstract][Full Text] [Related]
7. [Cytotoxicities of low dose anticancer agents combining lymphokine activated killer cell against ovarian adenocarcinoma cell line SKOV3].
Chen R; Pan L; Zhou S
Zhonghua Fu Chan Ke Za Zhi; 1999 Mar; 34(3):172-4. PubMed ID: 11263191
[TBL] [Abstract][Full Text] [Related]
8. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.
Fady C; Gardner AM; Gera JF; Lichtenstein A
Cancer Res; 1992 Feb; 52(4):764-9. PubMed ID: 1346583
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
[TBL] [Abstract][Full Text] [Related]
10. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
Kajiyama H; Shibata K; Terauchi M; Yamashita M; Ino K; Nawa A; Kikkawa F
Int J Oncol; 2007 Aug; 31(2):277-83. PubMed ID: 17611683
[TBL] [Abstract][Full Text] [Related]
11. [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
He YD; Peng ZL; Liu SL; Wang H; Pan XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):810-2. PubMed ID: 17953364
[TBL] [Abstract][Full Text] [Related]
12. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
13. BAD partly reverses paclitaxel resistance in human ovarian cancer cells.
Strobel T; Tai YT; Korsmeyer S; Cannistra SA
Oncogene; 1998 Nov; 17(19):2419-27. PubMed ID: 9824152
[TBL] [Abstract][Full Text] [Related]
14. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
15. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells.
Yamaue H; Tanimura H; Noguchi K; Iwahashi M; Tsunoda T; Tani M; Tamai M; Hotta T; Mizobata S; Arii K
J Clin Lab Immunol; 1991 Aug; 35(4):165-70. PubMed ID: 1668852
[TBL] [Abstract][Full Text] [Related]
17. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.
Li J; Liu P; Mao H; Wanga A; Zhang X
Oncol Rep; 2009 Jun; 21(6):1605-10. PubMed ID: 19424643
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.
Schmidt-Wolf IG; Lefterova P; Johnston V; Scheffold C; Csipai M; Mehta BA; Tsuruo T; Huhn D; Negrin RS
Cell Immunol; 1996 Apr; 169(1):85-90. PubMed ID: 8612299
[TBL] [Abstract][Full Text] [Related]
20. Effects of paclitaxel on the growth of normal, polyposis, and cancerous human colonic epithelial cells.
Sheppard BC; Rutten MJ; Meichsner CL; Bacon KD; Leonetti PO; Land J; Crass RC; Trunkey DD; Deveney KE; Deveney CW
Cancer; 1999 Apr; 85(7):1454-64. PubMed ID: 10193934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
